Furthermore, as a molecular biomarker, GSTP1 methylation could be used in conjunction with other prognostic indicators, such as tumor stage, to improve the accuracy of predicting patient outcomes and guide therapeutic decisions (Bakker et al., 2002). This evidence concerns the gene GSTP1 and neoplasm.